Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993044 · ClinicalTrials.gov registry record · Phase 1
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
A Phase 1 study, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00993044 is a Phase 1 study that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 13 participants.
The verdict
NCT00993044, a Phase 1 study, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with refractory solid tumors.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Vincristine
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993044
The ClinicalTrials.gov registry entry for NCT00993044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00993044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00993044 about?
NCT00993044 is a clinical study titled "A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin". This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with refractory solid tumors.
What is the current status of trial NCT00993044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-09. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00993044?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Vincristine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00993044?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.